02.16.21

Kala Pharmaceuticals Announces Eysuvis Now Covered by Express Scripts

Source: Kala Pharmaceuticals

02.12.21

Akorn Receives FDA Approval for Loteprednol Etabonate Ophthalmic Gel, 0.5%

Source: Akorn

01.07.21

Kala Pharmaceuticals Announces Commercial Availability of Eysuvis for the Treatment of Dry Eye Disease

Source: Kala Pharmaceuticals

11.16.20

Kala Pharmaceuticals Provides Update on Launch Plans for Eysuvis for the Treatment of Dry Eye Disease

Source: Kala Pharmaceuticals

10.27.20

Kala Pharmaceuticals Receives FDA Approval of Dry Eye Disease Treatment Eysuvis

Source: Kala Pharmaceuticals

05.26.20

Kala Pharmaceuticals Files New Drug Application to FDA for Eysuvis for Dry Eye Disease

Source: Kala Pharmaceuticals

05.04.20

Kala Pharmaceuticals Resubmits NDA for Eysuvis for Dry Eye Disease

Source: Kala Pharmaceuticals

03.09.20

Kala Pharmaceuticals Announces Statistically Significant Results in STRIDE 3 Trial of Dry Eye Disease Drug Eysuvis

Source: Kala Pharmaceuticals

04.22.19

Akorn Receives FDA Approval for Generic Loteprednol Etabonate

Source: Akorn

04.02.19

Bausch + Lomb Announces US Launch of Lotemax SM

Source: Bausch + Lomb

View more stories